WuXi

Charles River Labs to Acquire WuXi PharmaTech for $1.6B

Monday, April 26, 2010 08:32 AM

Preclinical contract research organization (CRO) Charles River Laboratories announced this morning plans to acquire Chinese CRO Wuxi PharmaTech in a deal valued at $1.6 billion.

More... »

WuXi Partners with Janssen to Meet GLP Standards in China Lab

Thursday, March 4, 2010 06:10 AM

Chinese CRO WuXi PharmaTech expanded its strategic collaboration with Johnson & Johnson Pharmaceutical Research and Development(a division of Janssen Pharmaceutica) to provide preclinical services to Janssen and to eventually offer Good Laboratory Practice (GLP) toxicology services at WuXi’s facility in Suzhou, China.

More... »

WuXi AppTec Partners with Qiagen to Develop Biomarkers

Tuesday, January 12, 2010 06:11 AM

Chinese contract research organization (CRO) WuXi AppTec has entered into a partnership with Netherlands holding company Qiagen to provide biomarker development, validation and personalized healthcare diagnostics. Neither company provided the financial details of the agreement.

More... »

WuXi Posts Another Strong Quarter

Wednesday, August 12, 2009 06:39 AM

Chinese contract research organization (CRO) WuXi PharmaTech reported another quarter of profit growth with a 7% increase compared to the same period last year despite a drop in revenues.

More... »

Dedicated Phase I Appoints New CMO

Friday, June 26, 2009 10:54 AM

Dedicated Phase I in Phoenix, Ariz., named a new chief medical officer to head its 80-bed phase I clinical research facility. Clark Springgate, M.D., Ph.D., brings more than 25 years' experience to the organization, having directed and participated in more than 256 clinical trials, including first-in-man and first-in-therapeutic-class studies.

More... »

ClearTrial Appoints New COO

Friday, March 27, 2009 11:17 AM

ClearTrial, a provider of clinical trial software, appointed Michael Bruns as the company’s new chief operating officer. Bruns will oversee ClearTrial’s global operations and help further develop and implement the company’s growth strategy. Prior to joining ClearTrial, Bruns was director of the Technology Investment Banking Group at Robert W. Baird, a global investment banking firm.

More... »

WuXi Revenues Up 87% in 2008

Thursday, March 26, 2009 07:28 AM

Chinese contract research organization (CRO) WuXi Pharmatech reported an 87% increase in 2008 revenues compared with 2007, with net revenues for continuing operations of $253.5 million. Fourth-quarter 2008 net revenues from continuing operations increased 74% to $64.4 million compared with fourth quarter 2007. The CRO’s non-GAAP net income for 2008 was $58.3 million, up 31% from $44.6 million in 2007.

More... »

WuXi Cuts U.S. Manufacturing Business

Wednesday, December 3, 2008 11:17 AM

Chinese contract research organization (CRO) WuXi PharmaTech is discontinuing its U.S. biologics manufacturing operations as of December 31. As a result, the company will cut about 100 manufacturing and supporting positions at its Philadelphia facility.

More... »

Etrials Appoints Permanent CEO

Friday, November 14, 2008 09:00 AM

Just a day after releasing disappointing third quarter results, Morrisville, N.C.-based eClinical company etrials named a new president and CEO, M. Denis Connaghan, replacing interim president and CEO Chuck Piccirillo. Piccirillo, who will resume his position as vice president of technology, has served as interim CEO since the resignation of Eugene “Chip” Jennings in July. Connaghan was formerly managing director within Marsh USA’s Global Operations.

More... »

WuXi Revenues Up 98%, Still Fall Short

Thursday, November 13, 2008 10:14 AM

WuXi Pharmatech released final third quarter earnings that reflected 98% revenue growth year-over-year but fell short of the company’s projected Q3 earnings.

More... »